Literature DB >> 14647484

Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice.

Isadora F Bielsky1, Shuang-Bao Hu, Kathleen L Szegda, Heiner Westphal, Larry J Young.   

Abstract

Considerable evidence suggests that arginine vasopressin (AVP) is critically involved in the regulation of many social and nonsocial behaviors, including emotionality. The existence of two AVP receptors in the brain, namely the V1a and V1b subtypes, and the lack of clear pharmacological data using selective agonists or antagonists, make it difficult to determine which receptor is responsible for the AVP-mediated effects on behavior. Here we report the behavioral effects of a null mutation in the V1a receptor (V1aR) in male mice. Male mice lacking functional V1aR (V1aRKO) exhibit markedly reduced anxiety-like behavior and a profound impairment in social recognition. V1aRKO performed normally on spatial and nonsocial olfactory learning and memory tasks. Acute central administration of AVP robustly stimulated stereotypical scratching and autogrooming in wild-type (WT), but not V1aRKO males. AVP and oxytocin (OT) mRNA and OT receptor-binding levels were similar in WT and V1aRKO mice. Given the current findings, the V1aR may provide a novel potential pharmacological target for social and affective disorders including autism, and anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14647484     DOI: 10.1038/sj.npp.1300360

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  169 in total

1.  Oxytocin, vasopressin and estrogen receptor gene expression in relation to social recognition in female mice.

Authors:  Amy E Clipperton-Allen; Anna W Lee; Anny Reyes; Nino Devidze; Anna Phan; Donald W Pfaff; Elena Choleris
Journal:  Physiol Behav       Date:  2011-11-03

2.  The AVPR1A gene and substance use disorders: association, replication, and functional evidence.

Authors:  Brion S Maher; Vladimir I Vladimirov; Shawn J Latendresse; Dawn L Thiselton; Rebecca McNamee; Moonsu Kang; Tim B Bigdeli; Xiangning Chen; Brien P Riley; John M Hettema; Howard Chilcoat; Christian Heidbreder; Pierandrea Muglia; E Lenn Murrelle; Danielle M Dick; Fazil Aliev; Arpana Agrawal; Howard J Edenberg; John Kramer; John Nurnberger; Jay A Tischfield; Bernie Devlin; Robert E Ferrell; Galina P Kirillova; Ralph E Tarter; Kenneth S Kendler; Michael M Vanyukov
Journal:  Biol Psychiatry       Date:  2011-04-22       Impact factor: 13.382

Review 3.  Hormonal mechanisms of cooperative behaviour.

Authors:  Marta C Soares; Redouan Bshary; Leonida Fusani; Wolfgang Goymann; Michaela Hau; Katharina Hirschenhauser; Rui F Oliveira
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2010-09-12       Impact factor: 6.237

4.  Two-hit exposure to polychlorinated biphenyls at gestational and juvenile life stages: 2. Sex-specific neuromolecular effects in the brain.

Authors:  Margaret R Bell; Bethany G Hart; Andrea C Gore
Journal:  Mol Cell Endocrinol       Date:  2015-11-24       Impact factor: 4.102

Review 5.  Vasopressin and alcohol: a multifaceted relationship.

Authors:  Kathryn M Harper; Darin J Knapp; Hugh E Criswell; George R Breese
Journal:  Psychopharmacology (Berl)       Date:  2018-11-03       Impact factor: 4.530

Review 6.  Oxytocin, vasopressin and pair bonding: implications for autism.

Authors:  Elizabeth A D Hammock; Larry J Young
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-12-29       Impact factor: 6.237

7.  Sex differences in vasopressin 1a receptor regulation of social communication within the lateral habenula and dorsal raphe of mice.

Authors:  Nicole Rigney; Rachael Beaumont; Aras Petrulis
Journal:  Horm Behav       Date:  2020-03-10       Impact factor: 3.587

8.  WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action.

Authors:  Callum Hicks; Linnet Ramos; Tristan A Reekie; Rajeshwar Narlawar; Michael Kassiou; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2015-03-13       Impact factor: 4.530

Review 9.  Lithium: a promising treatment for fragile X syndrome.

Authors:  Zhonghua Liu; Carolyn Beebe Smith
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

10.  Borderline personality disorder: current drug treatments and future prospects.

Authors:  Bayanne Olabi; Jeremy Hall
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.